{"name":"Exciva GmbH","slug":"exciva-gmbh","ticker":"","exchange":"","domain":"excivagmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EXV-801","genericName":"EXV-801","slug":"exv-801","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"EXV-801","genericName":"EXV-801","slug":"exv-801","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQOEhKQ0QteTk4bkJMQ2xjRGlNQ1N4bEtGQUx0SzJINEd2V05CdFBOeV94bklST2dMYmczTkVvVGVDZGFUMDRGcGwycDlBU1hYelN5ekMta1daajBFcHF3UUlZZUlpTHZmVVd6X2JJb0h3eVhMVlgyd21zR01veEFyOGlhTWN3LVVKb1JWMk94OHNEN1U?oc=5","date":"2026-01-20","type":"pipeline","source":"The Pharma Letter","summary":"Exciva raises $59 million in Series B funding - The Pharma Letter","headline":"Exciva raises $59 million in Series B funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOWHRtbnAxQ2F2WTZPYzJjWWJvb0tyZ2x6UU9wb3g5azBxQTlJbEJkNHppRXF5T3NXalZtOUVoU1NCMDBZWENxYzZzck9RbTBpOWpJaWtUX0h3b0NtbU50SlRYYTZ1Nm5rcW1MMjJhdEl1TEp0VHpIVFJrQVVYYWpKSE04eTljdGU4Y1NfeDdSUjlKTjJIdGtLWUN3?oc=5","date":"2026-01-20","type":"pipeline","source":"European Biotechnology Magazine","summary":"Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care - European Biotechnology Magazine","headline":"Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMVdXaGM4SUVjUXBBal85Q3dpZnhmdFNYdUNuaW13SE9jRXRCSDllUkRvaGtoelAzLU9PbzgyaEw0bWxmQmw5a0ZHZjNyVUF2VTZOUlhQQjRjSWR2MEVuVUduMk56OGVFWm40TFhkSkQ5cEU5X0lmUG9TYlEyRHJvMDB1aGwtY2tjRlptMWd6TXhfQ2Y5ajVZckx0el9VWjhSdTktM1JFdGk?oc=5","date":"2026-01-20","type":"trial","source":"BioWorld News","summary":"Exciva adds $59.9M series B for Alzheimer’s disease agitation trial - BioWorld News","headline":"Exciva adds $59.9M series B for Alzheimer’s disease agitation trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}